Korea FilingsFull brief — $39

Aprogen, Inc

(주)에이프로젠 · KOSPI: 007460 · Pharmaceuticals and medicinal chemicals

Key facts

Korean name
(주)에이프로젠
Market / ticker
KOSPI · 007460
Industry
Pharmaceuticals and medicinal chemicals
Established
1971-11-15
Fiscal year ends
December
Website
www.aprogen.com
DART corp code
00152385
Latest revenue
₩118.0B (FY2025)

Items worth checking

medium
Operating loss in both FY2024 and FY2025.
Source: Annual report FY2025
medium
Decision to issue convertible / warrant / exchangeable bonds — the filing states whether new or treasury shares back it — filed on 8 separate dates in the last 12 months, latest 2026-09-03.
Source: Material event report — Convertible bond issuance decision
medium
Capital reduction decided — filed 2026-02-23.
Source: Material event report — Capital reduction decision
low
Decision on paid-in capital increase (share dilution) — filed on 6 separate dates in the last 12 months, latest 2026-09-03.
Source: Material event report — Paid-in capital increase (rights offering) decision
low
Guarantee or collateral provided for another party — filed 2026-04-13.
Source: Decision to pledge collateral for another party

Financial summary

KRWFY2023FY2024FY2025
Revenue₩150.6B₩150.1B₩118.0B
Operating income−₩88.9B−₩86.8B−₩95.6B
Net income−₩97.3B−₩100.4B−₩140.6B
Total assets₩594.4B₩610.0B₩717.3B
Total liabilities₩176.7B₩169.9B₩258.7B
Total equity₩417.7B₩440.1B₩458.6B
Share capital₩132.4B₩152.1B₩164.7B

Consolidated statements · FY2025 operating margin -81.0% · liabilities to equity 56% · Annual report FY2025 (Korean original)

Auditor opinions

PeriodAuditorOpinion
Term 55 (current)삼덕회계법인Unqualified
Term 54 (prior)인덕회계법인Unqualified
Term 53 (two years prior)인덕회계법인Unqualified

Largest shareholder history

DateLargest shareholder (Korean)StakeCause (Korean)
2017년 11월 29일(주)지베이스—제3자배정 유상증자

Recent filings

DateFilingOriginal
2026-09-11Amended: Material event report — Paid-in capital increase (rights offering) decisionDART
2026-09-11Amended: Material event report — Convertible bond issuance decisionDART
2026-09-09Large shareholding (5%+) reportDART
2026-09-03Material event report — Paid-in capital increase (rights offering) decisionDART
2026-09-03Material event report — Convertible bond issuance decisionDART
2026-08-28Large shareholding (5%+) reportDART
2026-08-21Large shareholding (5%+) reportDART
2026-08-21Results of share or equity-linked bond issuance (voluntary)DART
2026-08-21Results of share or equity-linked bond issuance (voluntary)DART
2026-08-14Half-year report (2026.06)DART
2026-08-10Material event report — Convertible bond issuance decisionDART
2026-08-10Material event report — Convertible bond issuance decisionDART
2026-08-07Large shareholding (5%+) reportDART
2026-08-07Large shareholding (5%+) reportDART
2026-07-31Large shareholding (5%+) reportDART
2026-07-24Large shareholding (5%+) reportDART
2026-07-24Amended: Material event report — Convertible bond issuance decisionDART
2026-07-23Results of share or equity-linked bond issuance (voluntary)DART
2026-07-16Amended: Stock option grantDART
2026-07-16Large shareholding (5%+) reportDART

Showing the 20 most recent of 124 filings. The full brief lists all of them.

Full brief on Aprogen, Inc — $39 Get the full brief

For business customers. EU companies: enter your VAT number at checkout and no VAT is charged (reverse charge).

Other Korean companies in Pharmaceuticals and medicinal chemicals

Data generated 2026-09-16 from OpenDART.

This page summarizes public filings from DART, the official electronic disclosure system of Korea. It is not investment, credit or legal advice. Figures are shown in the currency the company reports in. Titles and labels are machine-translated and may contain errors — always check the linked original filing. Source: OpenDART, Financial Supervisory Service, Korea.